Oral administration of N-acetyl-seryl-aspartyl-lysyl-proline ameliorates kidney disease in both type 1 and type 2 diabetic mice via a therapeutic regimen

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Nitta, Kyoko ^a   Shi, Sen ^a   Nagai, Takako ^a   Kanasaki, Megumi ^a   Kitada, Munehiro ^a   Srivastava, Swayam Prakash ^a   Haneda, Masakazu ^b   Kanasaki, Keizo ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; CYSTATIN C; IMIDAPRIL; MICRORNA; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA LET 7; NACETYLSERYLASPARTYLLYSYLPROLINE; UNCLASSIFIED DRUG; ACE PROTEIN, HUMAN; DIPEPTIDYL CARBOXYPEPTIDASE; IMIDAZOLIDINE DERIVATIVE; OLIGOPEPTIDE; SERASPENIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; NONOBESE DIABETIC MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; IMIDAZOLIDINES; MICE; MICE, INBRED NOD; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A;

EID: 84964896883     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/9172157     Document Type: Article

References (40)

1. L. Xu, K. Kanasaki, M. Kitada, and D. Koya, "Diabetic angiopathy and angiogenic defects, " Fibrogenesis and Tissue Repair, vol. 5, no. 1, article 13, 2012.
2. K. Kanasaki, G. Taduri, and D. Koya, "Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis, " Frontiers in Endocrinology, vol. 4, article 7, 2013.
3. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, " The New England Journal of Medicine, vol. 329, no. 20, pp. 1456-1462, 1993.
4. B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, " The New England Journal of Medicine, vol. 345, no. 12, pp. 861-869, 2001.
5. P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen, "Effect of a multifactorial intervention on mortality in type 2 diabetes, "The New England Journal of Medicine, vol. 358, no. 6, pp. 580-591, 2008.
6. M. Kanasaki, T. Nagai, M. Kitada, D. Koya, and K. Kanasaki, "Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyllysyl- proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors, " Fibrogenesis and Tissue Repair, vol. 4, no. 1, article 25, 2011.
7. T. Nagai, K. Nitta, M. Kanasaki, D. Koya, and K. Kanasaki, "The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis, " Clinical and Experimental Nephrology, vol. 19, no. 1, pp. 65-74, 2015.
8. M. Mauer, B. Zinman, R. Gardiner et al., "Renal and retinal effects of enalapril and losartan in type 1 diabetes, " The New England Journal of Medicine, vol. 361, no. 1, pp. 40-51, 2009.
9. J. Cheng, W. Zhang, X. Zhang et al., "Effect of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a metaanalysis, " JAMA Internal Medicine, vol. 174, no. 5, pp. 773-785, 2014.
10. P. Ruggenenti, P. Cravedi, and G. Remuzzi, "Mechanisms and treatment of CKD, " Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 1917-1928, 2012.
11. H.-Y. Wu, J.-W. Huang, H.-J. Lin et al., "Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis, " British Medical Journal, vol. 347, Article ID f6008, 2013.
12. G. Wolf and E. Ritz, "Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications, " Kidney International, vol. 67, no. 3, pp. 799-812, 2005.
13. S. C. W. Tang, J. C. K. Leung, L. Y. Y. Chan, A. A. Eddy, and K. N. Lai, "Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy, " Kidney International, vol. 73, no. 3, pp. 288-299, 2008.
14. T. Nagai, M. Kanasaki, S. P. Srivastava et al., "N-acetyl-serylaspartyl- lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition, " BioMed Research International, vol. 2014, Article ID 696475, 12 pages, 2014.
15. K. Kanasaki, T. Nagai, K. Nitta, M. Kitada, and D. Koya, "Nacetyl- seryl-aspartyl-lysyl-proline: a valuable endogenous antifibrotic peptide for combating kidney fibrosis in diabetes, " Frontiers in Pharmacology, vol. 5, article 70, 2014.
16. M. Azizi, A. Rousseau, E. Ezan et al., "Acute angiotensinconverting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysylproline, " Journal of Clinical Investigation, vol. 97, no. 3, pp. 839-844, 1996.
17. K. Kanasaki, D. Koya, T. Sugimoto, M. Isono, A. Kashiwagi, and M. Haneda, "N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells, " Journal of the American Society of Nephrology, vol. 14, no. 4, pp. 863-872, 2003.
18. S. Pokharel, S. Rasoul, A. J. M. Roks et al., "N-Acetyl-Ser- Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts, " Hypertension, vol. 40, no. 2, pp. 155-161, 2002.
19. K. Shibuya, K. Kanasaki, M. Isono et al., "N-acetyl-serylaspartyl- lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice, " Diabetes, vol. 54, no. 3, pp. 838-845, 2005.
20. M. Omata, H. Taniguchi, D. Koya et al., "N-acetyl-serylasparlyl- lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established antiglomerular basement membrane nephritis, " Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 674-685, 2006.
21. J.-M. Liu, F. Lawrence, M. Kovacevic et al., "The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo, " Blood, vol. 101, no. 8, pp. 3014-3020, 2003.
22. D. Wang, O. A. Carretero, X.-Y. Yang et al., "N-acetyl-serylaspartyl- lysyl-proline stimulates angiogenesis in vitro and in vivo, "The American Journal of Physiology-Heart and Circulatory Physiology, vol. 287, no. 5, pp. H2099-H2105, 2004.
23. Y. Fromes, J.-M. Liu, M. Kovacevic, J. Bignon, and J. Wdzieczak- Bakala, "The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing, " Wound Repair and Regeneration, vol. 14, no. 3, pp. 306-312, 2006.
24. T. Huff, C. S. G. Muller, A. M. Otto, R. Netzker, and E. Hannappel, " thymosins, small acidic peptides with multiple functions, " International Journal of Biochemistry and Cell Biology, vol. 33, no. 3, pp. 205-220, 2001.
25. V. Koutrafouri, L. Leondiadis, K. Avgoustakis et al., "Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model, " Biochimica et Biophysica Acta (BBA)- General Subjects, vol. 1568, no. 1, pp. 60-66, 2001.
26. D. Philp, T. Huff, Y. S. Gho, E. Hannappel, and H. K. Kleinman, "The actin binding site on thymosin beta4 promotes angiogenesis, " The FASEB Journal, vol. 17, no. 14, pp. 2103-2105, 2003.
27. K. M. Malinda, A. L. Goldstein, and H. K. Kleinman, "Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells, " The FASEB Journal, vol. 11, no. 6, pp. 474-481, 1997.
28. N. Smart, C. A. Risebro, A. A. D. Melville et al., "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization, " Nature, vol. 445, no. 7124, pp. 177-182, 2007.
29. K. Kanasaki, M. Haneda, T. Sugimoto et al., "N-acetyl-serylaspartyl- lysyl-proline inhibitsDNA synthesis in humanmesangial cells via up-regulation of cell cyclemodulators, " Biochemical and Biophysical Research Communications, vol. 342, no. 3, pp. 758-765, 2006.
30. H. Sugimoto, G. Grahovac, M. Zeisberg, and R. Kalluri, "Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors, " Diabetes, vol. 56, no. 7, pp. 1825-1833, 2007.
31. K. Kanasaki, S. Shi, M. Kanasaki et al., "Linagliptinmediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelialto- mesenchymal transition in a therapeutic regimen, " Diabetes, vol. 63, no. 6, pp. 2120-2131, 2014.
32. S. Shi, S. P. Srivastava, M. Kanasaki et al., "Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition, " Kidney International, vol. 88, no. 3, pp. 479-489, 2015.
33. S. Mackensen-Haen, R. Bader, K. E. Grund, and A. Bohle, "Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate, " Clinical Nephrology, vol. 15, no. 4, pp. 167-171, 1981.
34. K. A. Nath, "Tubulointerstitial changes as a major determinant in the progression of renal damage, " American Journal of Kidney Diseases, vol. 20, no. 1, pp. 1-17, 1992.
35. R. A. Risdon, J. C. Sloper, and H. E. deWardener, "Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis, " The Lancet, vol. 2, no. 7564, pp. 363-366, 1968.
36. L. I. Schainuck, G. E. Striker, R. E. Cutler, and E. P. Benditt, "Structural-functional correlations in renal disease. Part II: the correlations, " Human Pathology, vol. 1, no. 4, pp. 631-641, 1970.
37. G. E. Striker, L. I. Schainuck, R. E. Cutler, and E. P. Benditt, "Structural-functional correlations in renal disease. Part I: a method for assaying and classifying histopathologic changes in renal disease, " Human Pathology, vol. 1, no. 4, pp. 615-630, 1970.
38. K. Kanasaki, M. Kitada, and D. Koya, "Pathophysiology of the aging kidney and therapeutic interventions, " Hypertension Research, vol. 35, no. 12, pp. 1121-1128, 2012.
39. K. Sharma, J. H. Ix, A. V. Mathewet al., "Pirfenidone for diabetic nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 22, no. 6, pp. 1144-1151, 2011.
40. D. de Zeeuw, T. Akizawa, P. Audhya et al., "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, " The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.